spacer
home > epc > Autumn 2018
PUBLICATIONS

European Pharmaceutical Contractor

epc
Autumn 2018

   
Text
PDF
bullet
Legal & Regulatory
Risk-Averse Cultures in New Product Development

Accelerating Development

Brion Regan at ERT discusses the surge in technological developments across the pharmaceutical industry, highlighting that their adoption across the field is low.
 
view
download pdf
Applying Quality Best Practice Principles

Quality Compliance

Patricia Santos-Serrao at MasterControl breaks the traditional view that clinical and manufacturing in life sciences operate in separate spheres by exploring the similarities they share.
 
view
download pdf
Clinical Partnerships in the NHS

Clinical Service

Bernard Ross at Sky Medical Technology puts forward the notion that the pharmaceutical and biotechnology industries need to prioritise clinical partnerships through clinician-first approaches.
 
view
download pdf
Application of Good Clinical Practice Principles

Right First and Every Time

One historic challenge in clinical research has been maintaining the balance between safety and effectiveness. Dr Suzanne Pavon at TFS explores different management approaches to combat this.
 
view
download pdf
   
spacer



Published quarterly in
February, May,
August, and November

News and Press Releases

Huge CPhI & P-MEC China a direct result of surging manufacturing

Shanghai, 22 July, 2019:CPhI and P-MEC China – organized by China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), Informa Markets, and Shanghai Sinoexpo Informa Markets – saw record numbers of attendees as the pharma market in China continues to grow. The three-day Shanghai event featured 3,200+ exhibiting companies, spanning the entire pharma supply chain, and provides a strong indication of the market’s overall growth patterns and future development.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement